
Nausheen Ahmed MD
Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology, Sickle Cell & Other Anemias
Associate Professor
Join to View Full Profile
2330 Shawnee Mission PkwyStop 5003Westwood, KS 66205
Phone+1 913-588-9832
Fax+1 423-408-7405
Dr. Ahmed is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Nausheen Ahmed is a Hematologist based in Westwood, KS with subspecialties in Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology, and Sickle Cell & Other Anemias. She completed her residency in Internal Medicine at the University of Connecticut, followed by fellowships in Hematology and Medical Oncology at UMass Chan and Case Western Reserve University respectively. Since 2019, she has been working as a Clinical Fellow at UH Cleveland Medical Center. Dr. Ahmed’s research, including studies on hematopoietic cell transplantation, CAR T cell therapy, and checkpoint inhibition in aggressive B-cell lymphomas, has been extensively published in professional journals. Among her several articles, one has been cited by four other publications.
Education & Training
- Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2017 - 2020
- UMass Chan - BaystateFellowship, Hematology and Medical Oncology, 2012 - 2015
- Aga Khan Medical CollegeClass of 2003
- University of ConnecticutResidency, Internal Medicine
Certifications & Licensure
- MO State Medical License 2021 - 2026
- KS State Medical License 2020 - 2025
- OH State Medical License 2017 - 2021
- TN State Medical License 2015 - 2019
- VA State Medical License 2015 - 2018
- MA State Medical License 2012 - 2015
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.Surbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, Ruta Brazauskas, Temitope Oloyede
Blood. 2025-04-08 - Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study.Othman Salim Akhtar, Temitope Oloyede, Ruta Brazauskas, Aimaz Afrough, Hamza Hashmi
Blood Advances. 2025-04-08 - 1 citationsLisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis.Peter A Riedell, Connor B Grady, Loretta J Nastoupil, Alejandro Luna, Nausheen Ahmed
Blood Advances. 2025-03-11
Press Mentions
- Should FDA’s Toxicity Guidance for CAR-T Be Changed?August 13th, 2024
- Toxicities Rare After Two Weeks of CAR T-cell Therapy InfusionJuly 31st, 2024
- FDA-Mandated CAR-T Monitoring Period Could Be HalvedJuly 24th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: